By Saqib Iqbal Ahmed NEW YORK (Reuters) -Trading in the options of Cerevel Therapeutics Holdings Inc experienced an unusual surge along with its stock price in the days before Wednesday’s announcement that AbbVie would buy the drug developer in a multi-billion dollar deal. AbbVie said after the market close on Wednesday it would buy Cerevel for about $8.7 billion in a bid to replace revenue as its huge-selling arthritis drug Humira faces a raft of new competitors. The announcement came minutes after Reuters reported a deal was near. Cerevel’s shares, which had already risen 42% over the past t…